Serum Thymidine Kinase 1 Activity in the Prognosis and Monitoring of Chemotherapy in Lung Cancer Patients: A Brief Report

@article{Nisman2014SerumTK,
  title={Serum Thymidine Kinase 1 Activity in the Prognosis and Monitoring of Chemotherapy in Lung Cancer Patients: A Brief Report},
  author={Benjamin Nisman and Hovav Nechushtan and Haim Biran and Hadas Gantz-Sorotsky and Nir Peled and Simon Gronowitz and Tamar Peretz},
  journal={Journal of Thoracic Oncology},
  year={2014},
  volume={9},
  pages={1568–1572}
}
Introduction: Thymidine kinase 1 (TK1) is a metabolic enzyme involved in DNA synthesis. Most standard treatment protocols for lung cancer (LC) include cytotoxic agents, which are potential modulators of TK1. We aimed to assess the prognostic significance of serum TK1 activity and its role in monitoring chemotherapy in LC patients. Methods: TK1 activity was measured using the DiviTum (Biovica) assay in sera from 233 patients with non–small-cell lung cancer (NSCLC), 91 with small-cell lung cancer… 

Thymidine kinase 1 in serum for prognosis, an investigation on routine individual adapted treatment of non-small cell lung carcinoma.

STK1p correlates significantly to survival and is an independent multivariate prognostic factor in NSCLC patients, and is a useful tool to combine with imager for a rational approach to increase the efficacy in early detection of tumor in lung cancer screening and assessment of individual adjusted therapy in NSClC patients.

Serum Concentration of Thymidine Kinase 1 (TK1) as a Tumor Marker in Soft Tissue Sarcomas

TK1 has limited use as a tumor marker in localized STS, and there is no association between increased preoperative TK1 and age, sex, tumor size, grade, and the presence of vascular invasion or necrosis.

Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors

Simple Summary Immune checkpoint inhibitors (ICI) are effective in fractions of patients with disseminated melanoma. Significant toxicity can also occur from the treatments, that, in addition, are

Thymidine kinase 1 through the ages: a comprehensive review

Compared to other proliferation markers, TK1 levels during S phase more accurately determine the rate of DNA synthesis in actively dividing tumors, and is potentially more advantageous than current biomarkers.

Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer

The rapid development of new therapies in metastatic breast cancer (MBC), entails a need for improved prognostic and monitoring tools. Thymidine kinase 1 (TK1) is involved in DNA synthesis and its

Preoperative Serum Thymidine Kinase Activity as Novel Monitoring, Prognostic, and Predictive Biomarker in Pancreatic Cancer

Pancreatic ductal adenocarcinomas reveal a significant increase in S-TK activity, which is associated with overall survival, especially in early tumor stages, and may be a useful parameter for monitoring nTx efficacy.

Serum thymidine kinase 1 levels correlate with clinical characteristics of esophageal squamous cell carcinoma.

The correlation of serum TK1 levels with clinical features of esophageal cancer and with patient survival suggest that serum Tk1 may serve as a valuable biomarker for predicting patient prognosis.

Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy

It is suggested that TK1 could be a potential prognostic, predictive and monitoring marker of early ET response in HR+/HER2neg MBC patients.

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

Serum TK1 activity is a promising pharmacodynamic marker of palbociclib in ER+ breast cancer, and its value in predicting response to CDK4/6 inhibitors warrants further investigation.

References

SHOWING 1-10 OF 16 REFERENCES

Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer

The magnitude of maximum fluorodeoxyglucose uptake in primary tumors and the serum TK1 level in patients with metastatic NSCLC were found to be independent prognostic predictors of overall survival.

Changes of thymidine kinase (TK) during adjuvant and palliative chemotherapy.

Thymidine kinase seems to be a suitable parameter for monitoring the effect of adjuvant and palliative chemotherapy in colorectal cancer.

Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients

Two recently developed immunoassays for serum thymidine kinase 1 (TK1) activity, DiviTum and Liaison, may be used for recurrence prediction in preoperative evaluation of BC patients.

Contribution of Thymidylate Synthase to Gemcitabine Therapy for Advanced Pancreatic Cancer

The expression of TS provides an alternative source of substrate for DNA synthesis and positively correlates with GEM resistance and shortened patient survival.

Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions

The literature surrounding hENT1 in pancreatic cancer is synthesized, the key outstanding questions are identified, and strategies to prospectively evaluate the clinical utility of hent1 in future clinical studies are suggested.

Evaluation of proliferation parameters in in vivo bromodeoxyuridine labelled lung cancers

It is concluded that the scores for PCNA and Ki67 antigen, immunohistochemically detected in ethanol fixed, paraffin embedded tissue reflect functional proliferative activity.

Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514.

The data demonstrate that inhibition of thymidylate synthase is a prominent mechanism for antitumor activity by LY231514, but important secondary sites of action exist for this multitargeted molecule.

Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression.

Data suggest that TK activity and NT expression have a common regulatory mechanism which is sensitive to endogenous dTTP pools and that the salvage pathway is a complex system of kinases coordinated with transport of nucleosides.

Etoposide increases equilibrative nucleoside transporter 1 activity and fluorothymidine uptake: screening of 60 cytotoxic agents.

Etoposide is identified as a potent inducer for ENT1 activity and [(3)H]FLT uptake and requests caution for the application of ENT1-mediated [(18)F] FLT flare for treatment monitoring.

5-Fluorouracil: mechanisms of action and clinical strategies

This work has shown that novel genes identified in DNA microarray profiling have the potential to identify novel genes that are involved in mediating resistance to 5-FU, and these genes might prove to be therapeutically valuable as new targets for chemotherapy, or as predictive biomarkers of response to5-FU-based chemotherapy.